Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

T-cell rich B-cell lymphoma

¹Department of Pathology, Christian Medical College, Hospital Vellore, India.

Indian Journal of Pathology & Microbiology

|December 1, 1994

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Utility of biopsy and frozen section in detecting malignancy within clinically suspicious verrucous growths: a retrospective study.

International journal of oral and maxillofacial surgery·2026

Same author

Evaluating the impact of image enhancement on radiomics feature stability in MRI of nasopharyngeal carcinoma.

Radiography (London, England : 1995)·2025

Same author

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Patient Selection and Outcomes in Reirradiation for Head and Neck Cancers: A Prospective Cohort Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Same author

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

ESMO open·2024